Clinical Trials Directory

We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.

We are doing this study to find out if radiation to the axillary (armpit) lymph nodes is equally effective and causes fewer side effects than surgical removal of the lymph nodes in patients with breast cancer.

We are doing this study to test how effectively a drug called emactuzumab works to reduce tumor size in people with tenosynovial giant cell tumors (TGCT).

We are doing this study to found out if a study drug called tarlatamab is a safe and effective option for patients with extensive stage small cell lung cancer (ES SCLC). We will compare the outcomes of how people do when they get a regimen of the study combined with durvalumab versus a regimen of durvalumab on its own.

We are doing this study to find out if avelumab is a safe and effective option for triple negative metastatic breast cancer when it is combined with different anti-cancer drugs.

We are doing this study to find out if an experimental drug called TL-895 (the study drug) is a safe and effective option for people with indolent systemic mastocytosis.

We will schedule you to attend 3 in-person study visits over the course of 6 months. The visits will take place either in Durham, NC or Kannapolis, NC. Each visit involves functional testing, having a small blood draw and providing a urine sample, completing a brief pain assessment, and answering questionnaires about your pain experiences and general wellbeing. After 12 months, we will ask you to fill out some additional questionnaires online.

We are doing this study to find the most effective, safe dose of an experimental drug called iadademstat (the study drug). We want to know if the study drug is beneficial for people with R/R AML that have the FLT3 mutation when it is given in combination with gilteritinib.